Yahoo Finance

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune ...
Yahoo Finance

Corner Bakery Cafe Highlights Variety and Value with Choose 2 Meal Deal

DALLAS, Sept. 23, 2026 /PRNewswire/ -- Corner Bakery Cafe is giving customers more ways to build a complete meal with its Choose 2 deal, available for $8.99 at participating corporate locations and $9 ...
Mena FN

Ernexa Therapeutics CEO Corner Highlights Appointment Of Dr. Robert J. Spiegel As Company Sharpens Oncology Focus And Advances ERNA-101 Toward The Clinic

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today released a ...
Mena FN

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform As Company Advances Toward Planned First-In-Human Phase 1 Study In 2026

(MENAFN- GlobeNewsWire - Nasdaq) CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling ...
manilatimes

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ovarian cancer remains one of the deadliest cancers affecting women worldwide. While treatment options have improved over time, many patients eventually experience disease recurrence and progression, ...